Search 

i-bank

Swissaustral is a worldwide specialist in Extreme Biotechnology developing innovative solutions for non-standard technological challenges in Life Sciences and different areas of Industry. Our company exploits the potential of extremophilic microorganisms and their unexplored metabolic pathways as a unique and diverse natural source for biocompounds of various industrial applications going from pharmaceutical, chemical, food and biotechnology.

Syneos Health is the only company in the biopharmaceutical Looking for services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.

Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.

We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.

We develop a medical device that treats cancer tumors as an alternative to surgery

SYNSIGHT developed the first drug discovery platform combining cell-based microscopy that train AI models, to generate new chemical entities. Your benefits will be to increase the productivity of your R&D and secure your drug discovery programs.

Our innovative platform and our technologies can be directly applied to protein-protein or protein-RNA interactions. Our bioassay is unique and patented and is able to qualify and quantify these interactions directly in human cell, and also of course the efficacy of small molecule modulators (Hit identification, "in cell IC50" measurement). This assay, easy to setup as medium or high-throughput screening level, is then able to train our AI models which generate new molecules.

We already successfully used our platform to study oncologic and neurodegenerative targets, for our own R&D or for customers. Our platform is able to manage different therapeutic area (oncology, virology, neurology, …), and different targets from your portfolio. We also propose to feed your portfolio and develop screening setup of our platform with exclusivity, with innovative targets like TPD-43, YB-1, alpha-SYN, BCL2, HUR, …